Last reviewed · How we verify
AZD5851
AZD5851 is a selective and potent inhibitor of the PI3K delta isoform.
AZD5851 is a selective and potent inhibitor of the PI3K delta isoform. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Relapsed or refractory follicular lymphoma.
At a glance
| Generic name | AZD5851 |
|---|---|
| Also known as | Cell Therapy |
| Sponsor | AstraZeneca |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting PI3K delta, AZD5851 disrupts the signaling pathways involved in B-cell activation and proliferation, which are key components in the development and progression of certain cancers. This mechanism of action is thought to contribute to the drug's therapeutic effects in treating various hematological malignancies.
Approved indications
- Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Relapsed or refractory follicular lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (PHASE1, PHASE2)
- LTFU for All Cell and Gene Therapy Studies
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD5851 CI brief — competitive landscape report
- AZD5851 updates RSS · CI watch RSS
- AstraZeneca portfolio CI